Sun Pharmaceutical Industries is currently trading at Rs. 865.95, up by 12.60 points or 1.48% from its previous closing of Rs. 853.35 on the BSE.
The scrip opened at Rs. 853.45 and has touched a high and low of Rs. 875.00 and Rs. 852.65 respectively. So far 69160 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 875.00 on 26-Aug-2014 and a 52 week low of Rs. 476.45 on 28-Aug-2013.
Last one week high and low of the scrip stood at Rs. 875.00 and Rs. 803.35 respectively. The current market cap of the company is Rs. 179456.00 crore.
The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.05% and 8.29% respectively.
Sun Pharmaceutical Industries’ arm - Caraco Pharmaceutical Laboratories, has initiated a recall of multiple lots of Cephalexin capsules from the US market. The recall of the 340,553 units of 500 mg and 113,677 units of 250 mg bottles is voluntarily initiated by the company through a letter to USFDA in June under ‘Class-II’ classification.
Cephalexin is an antibiotic that belongs to the family of medications known as cephalosporins. It is used to treat certain types of bacterial infections.
Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: